Bladder Cancer Treatment Market Expected to Surge to USD 11.33 Billion by 2034 Amid Increasing Incidence and Innovative Therapies#India#Immunotherapy#Pune#Bladder_Cancer#Targeted_Therapy
Bladder Cancer Treatment Market Expected to Surge to USD 11.33 Billion by 2034 Amid Increasing Incidence and Innovative Therapies
The bladder cancer treatment market is set to grow significantly, reaching USD 11.33 billion by 2034. This growth is fueled by rising disease incidence, advancements in immunotherapy, and targeted therapies reshaping treatment methods.
third-news.com
September 23, 2026 at 10:40 PM
Bladder Cancer Treatment Market Expected to Surge to USD 11.33 Billion by 2034 Amid Increasing Incidence and Innovative Therapies#India#Immunotherapy#Pune#Bladder_Cancer#Targeted_Therapy
Multi4 Medical's CE Mark Approval Revolutionizes Bladder Cancer Care in Europe#Sweden#Gothenburg#Bladder_Cancer#CE_Mark#Multi4_Medical
Multi4 Medical's CE Mark Approval Revolutionizes Bladder Cancer Care in Europe
Multi4 Medical receives CE mark for its innovative system, transforming bladder cancer treatment, enabling outpatient care without surgery.
third-news.com
May 5, 2026 at 4:01 PM
Multi4 Medical's CE Mark Approval Revolutionizes Bladder Cancer Care in Europe#Sweden#Gothenburg#Bladder_Cancer#CE_Mark#Multi4_Medical
Photocure and Artera Collaborate on Digital Pathology AI for Bladder Cancer Evaluation#Norway#Oslo#Bladder_Cancer#Photocure#Artera
Photocure and Artera Collaborate on Digital Pathology AI for Bladder Cancer Evaluation
A new collaboration between Photocure and Artera aims to enhance bladder cancer diagnostics through AI-powered pathology tests, supporting precision medicine.
third-news.com
June 8, 2026 at 5:47 PM
Photocure and Artera Collaborate on Digital Pathology AI for Bladder Cancer Evaluation#Norway#Oslo#Bladder_Cancer#Photocure#Artera
Photocure and Artera Forge Partnership to Enhance Bladder Cancer Diagnostics Using AI Technologies#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Artera
Photocure and Artera Forge Partnership to Enhance Bladder Cancer Diagnostics Using AI Technologies
Photocure and Artera announce a partnership focused on improving bladder cancer diagnostics with AI, promising personalized patient care and advanced detection methods.
third-news.com
June 8, 2026 at 5:36 PM
Photocure and Artera Forge Partnership to Enhance Bladder Cancer Diagnostics Using AI Technologies#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Artera
ImmVira Presents Promising MVR-T3011 Data for Bladder Cancer at ASCO GU 2026#China#Suzhou#Bladder_Cancer#ImmVira#MVR-T3011
ImmVira Presents Promising MVR-T3011 Data for Bladder Cancer at ASCO GU 2026
At the ASCO GU 2026 Conference, ImmVira showcased early results from a clinical trial of MVR-T3011 for BCG-naïve bladder cancer patients, signaling potential expansion in treatment options.
third-news.com
February 27, 2026 at 10:52 AM
ImmVira Presents Promising MVR-T3011 Data for Bladder Cancer at ASCO GU 2026#China#Suzhou#Bladder_Cancer#ImmVira#MVR-T3011
New Economic Analysis Highlights Cost-Effectiveness of BLC Over NBI Imaging for Bladder Cancer Treatment#Norway#Oslo#Bladder_Cancer#Photocure_ASA#BLC_Imaging
New Economic Analysis Highlights Cost-Effectiveness of BLC Over NBI Imaging for Bladder Cancer Treatment
A recent study published in 'The Journal of Medical Economics' reveals that Blue Light Cystoscopy (BLC) is more cost-effective than Narrow Band Imaging (NBI) for bladder cancer treatment.
third-news.com
May 4, 2026 at 6:37 AM
New Economic Analysis Highlights Cost-Effectiveness of BLC Over NBI Imaging for Bladder Cancer Treatment#Norway#Oslo#Bladder_Cancer#Photocure_ASA#BLC_Imaging
10x Genomics Partners with Cleveland Clinic to Enhance Bladder Cancer Diagnostics with Cutting-Edge Technology#United_States#Cleveland#Cleveland_Clinic #10x_Genomics#Bladder_Cancer
10x Genomics Partners with Cleveland Clinic to Enhance Bladder Cancer Diagnostics with Cutting-Edge Technology
A new collaboration between 10x Genomics and Cleveland Clinic aims to revolutionize bladder cancer diagnostics using advanced single-cell technologies. Discover the innovative approaches in research that may transform treatment outcomes.
third-news.com
June 17, 2026 at 1:54 PM
10x Genomics Partners with Cleveland Clinic to Enhance Bladder Cancer Diagnostics with Cutting-Edge Technology#United_States#Cleveland#Cleveland_Clinic #10x_Genomics#Bladder_Cancer
AUA 2026: The Impact of Blue Light Cystoscopy on High-Risk NMIBC Patient Management#USA#Washington_DC#Bladder_Cancer#Blue_Light#Photocure
AUA 2026: The Impact of Blue Light Cystoscopy on High-Risk NMIBC Patient Management
The 2026 AUA congress unveiled new studies showcasing the advantages of Blue Light Cystoscopy in managing high-risk non-muscle invasive bladder cancer (NMIBC), emphasizing cost-effectiveness.
third-news.com
May 18, 2026 at 3:47 PM
AUA 2026: The Impact of Blue Light Cystoscopy on High-Risk NMIBC Patient Management#USA#Washington_DC#Bladder_Cancer#Blue_Light#Photocure
New Health Economic Approach Analyzes Cost-Effectiveness of BLC vs NBI in Bladder Cancer Diagnostics#Norway#Oslo#Bladder_Cancer#Photocure#health_economics
New Health Economic Approach Analyzes Cost-Effectiveness of BLC vs NBI in Bladder Cancer Diagnostics
Photocure ASA recently unveiled a study comparing the cost-effectiveness of Blue Light Cystoscopy with Narrow Band Imaging for bladder cancer, revealing significant findings for healthcare appraisal.
third-news.com
May 4, 2026 at 6:36 AM
New Health Economic Approach Analyzes Cost-Effectiveness of BLC vs NBI in Bladder Cancer Diagnostics#Norway#Oslo#Bladder_Cancer#Photocure#health_economics
Multi4 Medical Marks Clinical Advancement in Bladder Cancer Treatment with New Outpatient Procedure#Sweden#Gothenburg#clinical_study#Bladder_Cancer#Multi4_Medical
Multi4 Medical Marks Clinical Advancement in Bladder Cancer Treatment with New Outpatient Procedure
Multi4 Medical's recent clinical study reveals a groundbreaking outpatient procedure for bladder cancer, promising safer and faster treatment for patients.
third-news.com
September 14, 2026 at 10:42 AM
Multi4 Medical Marks Clinical Advancement in Bladder Cancer Treatment with New Outpatient Procedure#Sweden#Gothenburg#clinical_study#Bladder_Cancer#Multi4_Medical
A New Hope for High-Risk Non-Muscle Invasive Bladder Cancer Treatment: The Approval of Inerekszo#Japan#Johnson_&_Johnson#Tokyo#Bladder_Cancer#Inerekszo
A New Hope for High-Risk Non-Muscle Invasive Bladder Cancer Treatment: The Approval of Inerekszo
Inerekszo's approval offers a transformative option for treating high-risk non-muscle invasive bladder cancer post-BCG therapy, raising new hopes for patients.
third-news.com
August 24, 2026 at 6:41 AM
A New Hope for High-Risk Non-Muscle Invasive Bladder Cancer Treatment: The Approval of Inerekszo#Japan#Johnson_&_Johnson#Tokyo#Bladder_Cancer#Inerekszo
New OPTUM Study Confirms Cost Neutrality of Blue Light Cystoscopy for Bladder Cancer#USA#Bladder_Cancer#Photocure_ASA#Blue_Light_Cystoscopy#Optum
New OPTUM Study Confirms Cost Neutrality of Blue Light Cystoscopy for Bladder Cancer
An OPTUM study reveals that blue light cystoscopy is cost-neutral compared to traditional white light cystoscopy in bladder cancer management, enhancing detection without increased costs.
third-news.com
August 11, 2026 at 7:05 AM
New OPTUM Study Confirms Cost Neutrality of Blue Light Cystoscopy for Bladder Cancer#USA#Bladder_Cancer#Photocure_ASA#Blue_Light_Cystoscopy#Optum
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Hexvix_Cysview
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress
Photocure ASA has announced its financial outcomes for Q2 2026, highlighting growth in Hexvix®/Cysview® revenues and strategic milestones in bladder cancer diagnostics.
third-news.com
July 29, 2026 at 6:43 AM
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Hexvix_Cysview
ImmVira's MVR-T3011 Achieves 100% Response Rate in Bladder Cancer Study#China#Suzhou#Bladder_Cancer#ImmVira#MVR-T3011
ImmVira's MVR-T3011 Achieves 100% Response Rate in Bladder Cancer Study
ImmVira Group announced a remarkable achievement of 100% complete response rate for MVR-T3011 in bladder cancer, showcased at ASCO.
third-news.com
June 1, 2026 at 12:03 AM
ImmVira's MVR-T3011 Achieves 100% Response Rate in Bladder Cancer Study#China#Suzhou#Bladder_Cancer#ImmVira#MVR-T3011
Verana Health Enhances Bladder Cancer Database with Real-World Data Insights#United_States#San_Francisco#Bladder_Cancer#RWD#Verana_Health
Verana Health Enhances Bladder Cancer Database with Real-World Data Insights
Verana Health has significantly updated its bladder cancer database, enhancing resources for genitourinary cancer research. This expansion aids in understanding disease impacts and patient outcomes.
third-news.com
May 21, 2026 at 2:20 PM
Verana Health Enhances Bladder Cancer Database with Real-World Data Insights#United_States#San_Francisco#Bladder_Cancer#RWD#Verana_Health
Global Bladder Cancer Survey Highlights Urgent Need for Treatment Innovation#United_States#Washington#Johnson_&_Johnson#Bladder_Cancer#Patient_Burden
Global Bladder Cancer Survey Highlights Urgent Need for Treatment Innovation
A groundbreaking survey reveals the profound emotional and physical burdens bladder cancer treatments impose on patients, sparking calls for innovation.
third-news.com
May 14, 2026 at 8:06 PM
Global Bladder Cancer Survey Highlights Urgent Need for Treatment Innovation#United_States#Washington#Johnson_&_Johnson#Bladder_Cancer#Patient_Burden
Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care#Norway#Oslo#Bladder_Cancer#Photocure#Hexvix
Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care
At the EAU 2026 Congress, Photocure presented innovative trials focusing on personalized treatments for bladder cancer, enhancing patient outcomes through advanced methodologies.
third-news.com
March 16, 2026 at 4:52 PM
Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care#Norway#Oslo#Bladder_Cancer#Photocure#Hexvix
Photocure's Innovative Trials at EAU 2026 Focus on Tailored Bladder Cancer Treatments#Norway#Oslo#Bladder_Cancer#Photocure#EAU_2026
Photocure's Innovative Trials at EAU 2026 Focus on Tailored Bladder Cancer Treatments
Photocure ASA showcases critical trials at EAU 2026 aimed at enhancing personalized care pathways for bladder cancer patients, emphasizing innovative solutions.
third-news.com
March 16, 2026 at 4:51 PM
Photocure's Innovative Trials at EAU 2026 Focus on Tailored Bladder Cancer Treatments#Norway#Oslo#Bladder_Cancer#Photocure#EAU_2026
Promising Phase 1 Results for Erda-iDRS in Bladder Cancer Patients Show High Response Rate#United_States#Johnson_&_Johnson#Raritan#Bladder_Cancer#Erda-iDRS
Promising Phase 1 Results for Erda-iDRS in Bladder Cancer Patients Show High Response Rate
Johnson & Johnson announced favorable findings from their Phase 1 study of Erda-iDRS, indicating an efficient treatment for non-muscle-invasive bladder cancer with an 89% response rate.
third-news.com
March 13, 2026 at 4:38 PM
Promising Phase 1 Results for Erda-iDRS in Bladder Cancer Patients Show High Response Rate#United_States#Johnson_&_Johnson#Raritan#Bladder_Cancer#Erda-iDRS
CorePlus and AIxMED Revolutionize Bladder Cancer Detection with AI-Driven Technology#United_States#San_Juan#Bladder_Cancer#CorePlus#AIxMed
CorePlus and AIxMED Revolutionize Bladder Cancer Detection with AI-Driven Technology
CorePlus and AIxMED unveil an innovative AI-powered solution, AIxURO, enhancing bladder cancer diagnosis efficiency and accuracy, revolutionizing patient care.
third-news.com
January 7, 2026 at 4:21 PM
CorePlus and AIxMED Revolutionize Bladder Cancer Detection with AI-Driven Technology#United_States#San_Juan#Bladder_Cancer#CorePlus#AIxMed
Innovative Cancer Treatment: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients#Japan#Tokyo#KEYTRUDA#PADCEV#Bladder_Cancer
Innovative Cancer Treatment: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients
The combination of PADCEV and Keytruda demonstrates significant improvements in survival rates for patients with muscle-invasive bladder cancer. This marks a potential new standard of care.
third-news.com
December 17, 2025 at 11:55 AM
Innovative Cancer Treatment: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients#Japan#Tokyo#KEYTRUDA#PADCEV#Bladder_Cancer
Blue Light Cystoscopy's Economic Advantage Explored in BRAVO Study Findings#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Blue_Light_Cystoscopy
Blue Light Cystoscopy's Economic Advantage Explored in BRAVO Study Findings
The BRAVO study reveals that while blue light cystoscopy incurs higher initial costs, lower recurrence rates lead to overall cost neutrality in bladder cancer care.
third-news.com
December 8, 2025 at 7:37 AM
Blue Light Cystoscopy's Economic Advantage Explored in BRAVO Study Findings#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Blue_Light_Cystoscopy
The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025#Norway#Oslo#Bladder_Cancer#Photocure_ASA#BRAVO_Study
The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025
The latest findings from the BRAVO study showcase the cost neutrality of blue light versus white light cystoscopy in treating bladder cancer, emphasizing real-world savings.
third-news.com
December 8, 2025 at 7:37 AM
The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025#Norway#Oslo#Bladder_Cancer#Photocure_ASA#BRAVO_Study
Johnson & Johnson's INLEXZO™ Shows Promising Results for Treating High-Risk Bladder Cancer#United_States#Johnson_&_Johnson#Raritan#Bladder_Cancer#INLEXZO™
Johnson & Johnson's INLEXZO™ Shows Promising Results for Treating High-Risk Bladder Cancer
Johnson & Johnson's recent SunRISe-1 study indicates that INLEXZO™ significantly boosts disease-free survival rates in high-risk bladder cancer patients unresponsive to BCG treatment.
third-news.com
December 5, 2025 at 9:30 PM
Johnson & Johnson's INLEXZO™ Shows Promising Results for Treating High-Risk Bladder Cancer#United_States#Johnson_&_Johnson#Raritan#Bladder_Cancer#INLEXZO™
New Study Highlights Economic Benefits of Blue Light Cystoscopy in Managing Bladder Cancer Across Europe#Norway#Oslo#Bladder_Cancer#Photocure#BLC
New Study Highlights Economic Benefits of Blue Light Cystoscopy in Managing Bladder Cancer Across Europe
A recent study reveals that the use of blue light cystoscopy (BLC) offers significant clinical and economic advantages for non-muscle-invasive bladder cancer in four European countries.
third-news.com
November 19, 2025 at 7:39 AM
New Study Highlights Economic Benefits of Blue Light Cystoscopy in Managing Bladder Cancer Across Europe#Norway#Oslo#Bladder_Cancer#Photocure#BLC